Chairman & CEO of Paragon Biosciences Works with MATTER

Jeff Aronin, Chairman and Chief Executive Officer of Paragon Biosciences, has over two decades of experience in the bioscience field. His innovative strategies and experience developing biotech and innovative healthcare companies is pushing Paragon forward. Aronin earned an MBA from DePaul University and a bachelor’s of science degree from Northern Illinois University. One of his distinct career accolades includes being named an Aspen Institute Henry Crown Fellow.

In addition to being the Chairman and CEO of Paragon Biosciences, Jeff Aronin is also the Chairman and CEO of Paragon Pharmaceutical Capital. The latter is described as an innovative and dynamic global investment firm which is focused on establishing, fostering, and managing life science companies.

 

The Company That Leads Biotechnology

Paragon Biosciences is the parent company or umbrella company which helps create and establish the growth of biotechnology companies. Currently there are four companies powered by Paragon which each have niche developments yet employ the same patient-centric tactics. Castle Creek Pharmaceuticals is constantly in the process of developing cutting edge therapies for patients with debilitating dermatologic conditions. Harmony Biosciences is focused on patients with central nervous system and sleep disorders and creating the innovative medications to treat associated disorders (http://weeklyopinion.com/2018/03/jeff-aronin-improves-lives/). Precision BP focuses on rare genetic oncology diseases and researches the potential complex treatments for such diseases. Decade Pharmaceuticals is dedicated to the research and development of Alzheimer’s therapies to improve outcomes and quality of life for such patients.

Over 6,000 identified diseases do not have treatments at this time. Paragon is working methodically to ensure that they are able to make a difference in that daunting figure. At the core of their philosophy is a simple approach to identifying patient needs, carefully reviewing the science behind the needs, and then creating the company structure to focus on addressing those needs. This philosophy is what drives their proven model of drug development. In fact, Paragon has 13 medications which have received FDA approval within the past decade. This is a pace typically only seen with the largest pharmaceutical companies, but Paragon Biosciences is driven by their patient centered goal to succeed in bringing new medications to fruition.